Epigenomics AG (Epigenomics AG) COGS-to-Revenue : 0.08 (As of Jun. 2023)

View and export this data going back to . Start your Free Trial

What is Epigenomics AG COGS-to-Revenue?

Epigenomics AG's Cost of Goods Sold for the three months ended in Jun. 2023 was $0.01 Mil. Its Revenue for the three months ended in Jun. 2023 was $0.08 Mil.

Epigenomics AG's COGS to Revenue for the three months ended in Jun. 2023 was 0.08.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Epigenomics AG's Gross Margin % for the three months ended in Jun. 2023 was 92.11%.

Epigenomics AG COGS-to-Revenue Historical Data

The historical data trend for Epigenomics AG's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Epigenomics AG COGS-to-Revenue Chart

Epigenomics AG Annual Data

Trend

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

COGS-to-Revenue

Get a 7-Day Free Trial

0.29

0.22

0.17

0.02

0.25

Epigenomics AG Quarterly Data
	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23
COGS-to-Revenue	Get a 7-Day Free Trial															0.25	0.25	0.27	0.28	0.08

Epigenomics AG COGS-to-Revenue Calculation

Epigenomics AG's COGS to Revenue for the fiscal year that ended in Dec. 2022 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.127	/	0.514
	=	0.25

Epigenomics AG's COGS to Revenue for the quarter that ended in Jun. 2023 is calculated as

COGS to Revenue	=	Cost of Goods Sold	/	Revenue
	=	0.006	/	0.076
	=	0.08

Epigenomics AG (OTCPK:EPGNF) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Epigenomics AG's Gross Margin % for the three months ended in Jun. 2023 is calculated as:

Gross Margin %	=	1	-	COGS to Revenue
	=	1	-	Cost of Goods Sold / Revenue
	=	1	-	0.006 / 0.076
	=	92.11 %

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.

Epigenomics AG COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Epigenomics AG's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Epigenomics AG (Epigenomics AG) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Epigenomics AG (OTCPK:EPGNF) » Definitions » COGS-to-Revenue

Comparable Companies

Traded in Other Exchanges

ECX:Germany

Address

Geneststrasse 5, Berlin, BB, DEU, 10829

Website

https://www.epigenomics.com

Epigenomics AG is a molecular diagnostics company, that focuses on developing and commercializing in vitro diagnostic liquid biopsy tests for the screening, early detection, and diagnosis of cancer. The company develops and markets procedures and devices for the production in quantity of particular epigenetic parameters such as DNA methylation patterns as well as the information technology bases necessary for their procurement and evaluation. It is engaged in the development of novel molecular diagnostic products for cancer. The company products include Epi proColon, Epi BiSKit, HCCBloodTest, and Epi proLung. The company operates in Europe, Asia, and North America, majority of its revenue derives from Asia.

Epigenomics AG (Epigenomics AG) Headlines

From GuruFocus

Encode Ideas, L.P. to host Virtual 1x1 Webinar with Epigenomics AG (ECX.DE, EPGNF) on Tuesday, July 28th at 10:30 AM ET

By ACCESSWIRE ACCESSWIRE • 07-23-2020